ArticleFrontiers in immunology2024

Successful treatment with tislelizumab plus chemotherapy for SMARCA4-deficient undifferentiated tumor: a case report.

Wen Dong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.